Summarized by Masters of Longevity from Fight Aging!.
Targeting inflammation to treat atherosclerosis — a narrative review of the scientific rationale, therapeutic strategies under study, and the clinical/regulatory landscape readers will explore.
Key Takeaways
- Atherosclerosis is driven not only by lipids but also by chronic vascular inflammation involving NLRP3, IL-1β, and IL-6 signaling.
- Clinical trials show anti-inflammatory treatments like IL-1β inhibition and colchicine reduce cardiovascular events independent of lipid lowering.
- Widespread clinical use is limited by infection risk, high costs, and the lack of sensitive biomarkers to identify active vascular inflammation.
